Current Headlines
-
Elix, An AI Drug Discovery Company, And Tohoku University Enter Joint Research Agreement To Advance AI Drug Discovery
10/2/2025
Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) and the Graduate School of Life Sciences at Tohoku University (Dean: Kouki Hikosaka / Headquarters: Miyagi; hereinafter “Tohoku University”) are pleased to announce the signing of a joint research agreement aimed at advancing drug discovery using AI technologies.
-
XenoSTART And Minerva Imaging Expand Partnership To Deliver Integrated PDX-Radiopharmaceutical Drug Development Platform
10/2/2025
The START Center for Cancer Research ("START"), its preclinical division XenoSTART, and Minerva Imaging today announced an expansion of their decade-long partnership to establish the industry's most comprehensive integrated platform for radiopharmaceutical drug development.
-
QuantHealth Secures Strategic Investment From Sanofi Ventures To Accelerate AI-Driven Clinical Trials
10/1/2025
QuantHealth, a pioneer in AI-driven clinical trial simulation, announced a strategic investment from Sanofi Ventures, the venture capital arm of global healthcare leader Sanofi. The investment will accelerate QuantHealth’s efforts to bring scalable, patient-level simulations and digital twin technologies to the forefront of drug development, bringing its total funds raised to $30M.
-
Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation By U.S. FDA For The Treatment Of Alzheimer's Disease
10/1/2025
Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a potential best-in-class anti-microtubule binding region-tau (anti-MTBR-tau) antibody currently in Phase 2 development for the treatment of early Alzheimer’s disease.
-
Pharming Group Announces U.S. FDA Acceptance And Priority Review Of Supplemental New Drug Application For Leniolisib In Children With APDS Aged 4 To 11 Years
10/1/2025
Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.
-
Illumina Launches New Business To Accelerate Technology And Data-Driven Discovery
10/1/2025
Illumina, Inc. (NASDAQ: ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic insights driven by the need of researchers and pharma companies to access and interpret ever larger-scale multiomic data.
-
A New Analytical Tool To Optimize The Potency And Selectivity Of Drugs
9/30/2025
Researchers at Baylor College of Medicine have developed a powerful new data analysis method named COOKIE-Pro (Covalent Occupancy Kinetic Enrichment via Proteomics) that provides a comprehensive, unbiased view of how a class of drugs, called covalent inhibitors, interacts with proteins throughout the cell.
-
Disc Medicine Announces Submission Of New Drug Application (NDA) To US FDA For Accelerated Approval Of Bitopertin For Patients With Erythropoietic Protoporphyria (EPP)
9/30/2025
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bitopertin for patients aged 12 years and older with erythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP).
-
TileDB, Kepler AI, And Tahoe Therapeutics Partner To Transform Single-Cell Data Analysis With AI-Powered Platform
9/30/2025
TileDB, Inc., Kepler AI, and Tahoe Therapeutics today announced a groundbreaking partnership to create the first public-facing platform that enables researchers to run sophisticated AI agent-based queries on massive single-cell datasets at unprecedented scale.
-
BioLineRx Ltd. And Hemispherian AS Establish Joint Venture To Develop GLIX1, A First-In-Class, Oral, Small Molecule Targeting DNA Damage Response In Glioblastoma And Other Cancers
9/29/2025
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a Norwegian biotech company focused on small molecule cancer therapeutics, today announced the establishment of a joint venture (JV) to develop GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma (GBM) and other cancers.